Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 1/2011

01-03-2011 | Original Paper

A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review

Authors: Chunming Gong, Xueying Hu, Yong Gao, Yunfei Cao, Feng Gao, Zengnan Mo

Published in: Medical Oncology | Issue 1/2011

Login to get access

Abstract

Studies revealing conflicting results on the role of NAT1 or NAT2 phenotypes on prostate cancer risk led us to perform a meta-analysis to investigate the association of these polymorphisms and prostate cancer risk. The meta-analysis included six studies with NAT1 genotyping (610 prostate cancer cases and 713 controls), and 10 studies with NAT2 genotyping (1,253 cases and 1,722 controls). The fixed effects odds ratio was 0.96 [95% confidence interval (95% CI): 0.75, 1.21; I 2 = 32.9%, P for heterogeneity = 0.189] for the NAT1 genotype, and the random effects odds ratio was 1.10 (95% CI: 0.87, 1.39; I 2 = 49.1%, P for heterogeneity = 0.039) for the NAT2 genotype. For NAT2 polymorphism, a statistically significant association between NAT2 polymorphism and prostate cancer appeared in Asians, but not in Caucasians. In conclusion, the NAT1 or NAT2 phenotypes detoxify carcinogens and their reactive intermediates are unlikely to be the cause of PCa development.
Literature
1.
Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics. 1995;5(2):59–63.PubMedCrossRef
2.
Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9(3):193–203.PubMedCrossRef
3.
Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA. 1991;88:5237–41.PubMedCrossRef
4.
Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA. 1991;88:6333–7.PubMedCrossRef
5.
Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun. 1991;177:1252–7.PubMedCrossRef
6.
Costa S, Pinto D, Morais A, et al. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population. Prostate. 2005;64:246–52.PubMedCrossRef
7.
Smith G, Stanley LA, Sim E, et al. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65.PubMed
8.
d’Errico A, Taioli E, Chen X. Genetic metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers. 1996;1:149–73.CrossRef
9.
Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9:29–42.PubMed
10.
11.
Agundez JA, Martinez C, Olivera M, et al. Expression in human prostate of drug-and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer. 1998;78:1361–7.PubMedCrossRef
12.
Lawson T, Kolar C. Human prostate epithelial cells metabolize chemicals of dietary origin to mutagens. Cancer Lett. 2002;175:141–6.PubMedCrossRef
13.
Hein DW, Leff MA, Ishibe N, et al. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen. 2002;40(3):161–7.PubMedCrossRef
14.
Bruhn C, Brockmöller J, Cascorbi I, et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol. 1999;58:1759–64.PubMedCrossRef
15.
Labuda D, Krajinovic M, Richer C, et al. Rapid detection of CYP1A1, CYP2D6 and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal Biochem. 1999;275:84–92.PubMedCrossRef
16.
Lo-Guidice JM, Allorge D, Chevalier D, et al. Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay. Pharmacogenetics. 2002;10:293–300.CrossRef
17.
Smelt VA, Mardon HJ, Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol. 1998;83:149–57.PubMedCrossRef
18.
Smelt VA, Upton A, Adjaye J, et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Hum Mol Genet. 2000;9:1101–7.PubMedCrossRef
19.
Katoh T, Kaneko S, Boissy R, et al. A pilot study testing the association between N-acetyltransferase 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis. 1998;19:1803–7.PubMedCrossRef
20.
Sekine A, Saito S, Iida A, et al. Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population. J Hum Genet. 2001;46:314–9.PubMedCrossRef
21.
Zhao B, Lee E, Yeoh PN, et al. Detection of mutations and polymorphism of N-acetyltransferase 1 gene in Indian, Malay and Chinese populations. Pharmacogenetics. 1998;8:299–304.PubMedCrossRef
22.
Lin HJ, Probst-Hensch NM, Hughes NC, et al. Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics. 1998;8:269–81.PubMedCrossRef
23.
Upton A, Johnson N, Sandy J, et al. Arylamine N-acetyltransferases—of mice, men and microorganisms. Trends Pharmacol Sci. 2001;22:140–6.PubMedCrossRef
24.
Abe M, Deguchi T, Suzuki T. The structure and characterisation of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population. Biochem Biophys Res Commun. 1993;191:811–6.PubMedCrossRef
25.
Hickman D, Sim E. N-Acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991;42:1007–14.PubMedCrossRef
26.
Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem. 1992;267:18140–7.PubMed
27.
Deguchi T, Mashimo M, Suzuki T. Correlations between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biol Chem. 1990;265:12757–60.PubMed
28.
Sim E, Hickman D. Polymorphism in human N-acetyltransferase—the case of the missing allele. Trends Pharmacol Sci. 1991;12:211–3.CrossRef
29.
Henning S, Cascorbi I, Münchow B, et al. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999;9:103–11.PubMedCrossRef
30.
Westphal GA, Reich K, Schultz TG, et al. N-Acetyltransferase 1 and 2 polymorphisms in para-substituted arylamine-induced contact allergy. Br J Dermatol. 2000;142:1121–7.PubMedCrossRef
31.
32.
33.
Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14:143–9.PubMedCrossRef
34.
35.
Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am. 2003;30:209–17.PubMedCrossRef
36.
Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008;179:892–5.PubMedCrossRef
37.
Wang CY, Debiec-Rychter M, Schut HA, et al. N-Acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis. 1999;20:1591–5.PubMedCrossRef
38.
Hein DW, Grant DM, Sim E. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics. 2000;10(4):291–2.PubMedCrossRef
39.
Beebe-Dimmer JL, Levin AM, Ray AM, et al. Chromosome 8q24 markers: risk of early-onset and familial prostate cancer. Int J Cancer. 2008;122(12):2876–9.PubMedCrossRef
40.
Slattery ML, Edwards SL, Samowitz W, et al. Associations between family history of cancer and genes coding for metabolizing enzymes (United States). Cancer Causes Control. 2000;11(9):799–803.PubMedCrossRef
41.
Agúndez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9(6):520–31.PubMedCrossRef
42.
Dalhoff K, Buus Jensen K, Enghusen Poulsen H. Cancer and molecular biomarkers of phase 2. Methods Enzymol. 2005;400:618–27.PubMedCrossRef
43.
Reszka E, Wasowicz W. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Minirev Neoplasma. 2002;49(4):209–16.
44.
Kinoshita Y, Singh A, Rovito PM Jr, et al. Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer. 2004;3(2):83–6.PubMed
45.
Hooker S, Bonilla C, Akereyeni F, et al. NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis. 2008;11(4):349–56.PubMedCrossRef
46.
Rovito PM Jr, Morse PD, Spinek K, et al. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(1):69–74.PubMedCrossRef
47.
Wang CY, Jones RF, Debiec-Rychter M, et al. Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res. 2002;22(6B):3529–35.PubMed
48.
Wadelius M, Autrup JL, Stubbins MJ, et al. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics. 1999;9(3):333–40.PubMedCrossRef
49.
Srivastava DS, Mittal RD. Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population. BMC Urol. 2005;5:12.PubMedCrossRef
50.
Gao JP, Huang YD, Yang GZ, et al. Relationship between genetic polymorphisms of metabolizing enzymes and prostate cancer. Zhonghua Nan Ke Xue. 2003;9(1):32–5.PubMed
51.
Hamasaki T, Inatomi H, Katoh T, et al. N-Acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol. 2003;10(3):167–73.PubMedCrossRef
52.
Fukutome K, Watanabe M, Shiraishi T, et al. N-Acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development. Cancer Lett. 1999;136(1):83–7.PubMedCrossRef
53.
Iguchi T, Sugita S, Wang CY, et al. MnSOD genotype and prostate cancer risk as a function of NAT genotype and smoking status. In Vivo. 2009;23(1):7–12.PubMed
54.
Blettner M, Sauerbrei W, Schlehofer B, et al. Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol. 1999;28:1–9.PubMedCrossRef
55.
Slager SL, Zarfas KE, Brown WM, et al. Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. Prostate. 2006;66:173–9.PubMedCrossRef
56.
Xu J, Gillanders EM, Isaacs SD, et al. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate. 2003;57:320–5.PubMedCrossRef
57.
Wiklund F, Gillanders EM, Albertus JA, et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate. 2003;57:290–7.PubMedCrossRef
58.
Edwards S, Meitz J, Eles R, et al. Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. Prostate. 2003;57:270–9.PubMedCrossRef
59.
Stanford JL, Fitzgerald LM, McDonnell SK, et al. Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage. Hum Mol Genet. 2009;18(10):1839–48.PubMedCrossRef
60.
Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645–9.PubMedCrossRef
61.
Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007;39:631–7.PubMedCrossRef
62.
Eeles RA, Kote-Jarai J, Giles GG, et al. Identification of multiple novel prostate cancer susceptibility loci by a genome-wide association study. Nat Genet. 2008;40:316–21.PubMedCrossRef
63.
Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet. 2008;40:310–5.PubMedCrossRef
64.
Metadata
Title
A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review
Authors
Chunming Gong
Xueying Hu
Yong Gao
Yunfei Cao
Feng Gao
Zengnan Mo
Publication date
01-03-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9423-5

Other articles of this Issue 1/2011

Medical Oncology 1/2011 Go to the issue

Original Paper

Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas

Original Paper

A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib

Original paper

Prognostic value of β-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma

Original Paper

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer

Original paper

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

Original Paper

Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits